Core Insights - Sonnet BioTherapeutics Holdings, Inc. announced that its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference, highlighting its focus on targeted immunotherapeutic drugs [1] Company Overview - Sonnet is an oncology-focused biotechnology company that utilizes a proprietary platform known as FHAB (Fully Human Albumin-Binding) for developing targeted biologic drugs [2] - The FHAB technology employs a fully human single chain antibody fragment that binds to human serum albumin for targeted transport to tumor and lymphatic tissues, aiming to enhance the safety and efficacy of immune-modulating biologic drugs [2] - The lead program, SON-1010 (IL-12-FHAB), is in development for advanced solid tumors, certain sarcomas, and platinum-resistant ovarian cancer, currently evaluated in a Phase 1/2a study in collaboration with Roche [2] - The second product candidate, SON-1210 (IL12-FHAB-IL15), is being developed for solid tumors in partnership with the Innovative Immuno-Oncology Consortium, with plans for a Phase 1/2a study for pancreatic ductal adenocarcinoma [2] - The SON-080 program, focusing on low-dose rhIL-6 for Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy, has shown promising results in a Phase 1b/2a clinical trial and is advancing into a Phase 2 study in India under a license agreement with Alkem Laboratories [2]
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference